Lino Biotech

Lino Biotech, founded in 2018 and based in Zurich, Switzerland, is a platform technology company specializing in advanced label-free biosensing. Its flagship product, the MACS® Matchmaker instrument, utilizes proprietary focal molography technology to characterize biomolecular interactions—such as affinity, kinetics, and specificity—directly in complex, biologically relevant environments. This capability addresses a critical bottleneck in early-stage drug discovery by providing more physiologically relevant data for hit validation and binder characterization, particularly for challenging targets like GPCRs. As a Miltenyi Biotec company, Lino leverages significant corporate backing for commercial scaling and R&D.

Focal molography, a label-free optical biosensing technology enabling real-time, multiplexed analysis of biomolecular interactions directly in complex biological samples.

Lino Biotech competes in the label-free interaction analysis market against established players like Cytiva (Biacore SPR systems), Sartorius (BLItz/Octet systems), and Nicoya Lifesciences. Its primary differentiation is the claimed robustness and drift-free performance in complex biological matrices, a segment where traditional technologies often struggle with non-specific binding and signal artifacts.